ReviewNature reviews. Gastroenterology & hepatology2021
COVID-19 and liver disease: mechanistic and clinical perspectives.
Review in Nature reviews. Gastroenterology & hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 246 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
246 citing papers in PubMed, 1 synthesis or guideline pooled it, 386 citations in OpenAlex.
- Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method.International journal of molecular sciences · 2022Pooled it
- High prevalence of autoantibodies neutralizing type I IFNs in Japanese patients with hepatitis C.Journal of human immunity · 2026Article
- Gut Microbiota, Immunity, and Metabolism in the Progression From Chronic Liver Disease to Hepatocellular Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Multiparametric Ultrasound Assessment of Long-Term Liver Damage in COVID-19: Results of a Three-Year Follow-Up Study.Medicina (Kaunas, Lithuania) · 2026Article
- Exosomal ORF3a mediates lung-liver axis to dysregulate hepatic lipid metabolism in mild COVID-19.Cell discovery · 2026Article
- Changes in Disease Severity and Outcomes Among Electively Admitted Cirrhosis Patients During the COVID-19 Era.Healthcare (Basel, Switzerland) · 2026Article
- The risk of kidney disease increases following SARS-CoV-2 infection compared to influenza.Communications medicine · 2026Article
- Assessing the Long-Term Impact of the COVID-19 Pandemic on Hospital Outcomes in Patients with Decompensated Liver Cirrhosis.Medicina (Kaunas, Lithuania) · 2026Article
- Assessment of biochemical and hematological profiles in outpatients with serological evidence of SARS-CoV-2 infection.Frontiers in medicine · 2026Article
- Comparison of biomarkers and laboratory results in unaffected, moderate, and severe COVID-19 recovered patients.Future science OA · 2025Article
- Review
- Liver-Related COVID-19 Consequences: Dynamics of Liver Health in 2.5 Years.Journal of clinical medicine · 2025Article
- Mortality and associated factors among hospitalised COVID-19 patients in Lira regional referral hospital, a cross-sectional study.BMJ open · 2025Article
- COVID-19 and chronic liver disease: results from the 1219 patients French registry.Scientific reports · 2025Article
- Possible link between steatotic liver diseases, severe COVID-19 and cognitive impairment in post-COVID-19 syndrome.Infection · 2025Article
- Article
- Contemporary burden of mortality from chronic liver disease by sex and race/ethnicity in the United States.Clinical and molecular hepatology · 2025Article
- COVID-19 and Liver Injury, Beyond the First Pandemic Waves: Clinical and Immune-Virological Features.Journal of viral hepatitis · 2025Article
- Impact of COVID-19 on disease-specific mortality, healthcare resource utilization, and disease burden across a population over 1 billion in 31 countries: an interrupted time-series analysis.EClinicalMedicine · 2025Article
- Impact of COVID-19 Vaccination on Hospitalization and Mortality: A Comparative Analysis of Clinical Outcomes During the Early Phase of the Pandemic.Infectious disease reports · 2025Article
186 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
Abstract
Our understanding of the hepatic consequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its resultant coronavirus disease 2019 (COVID-19) has evolved rapidly since the onset of the pandemic. In this Review, we discuss the hepatotropism of SARS-CoV-2, including the differential expression of viral receptors on liver cell types, and we describe the liver histology features present in patients with COVID-19. We also provide an overview of the pattern and relevance of abnormal liver biochemistry during COVID-19 and present the possible underlying direct and indirect mechanisms for liver injury. Furthermore, large international cohorts have been able to characterize the disease course of COVID-19 in patients with pre-existing chronic liver disease. Patients with cirrhosis have particularly high rates of hepatic decompensation and death following SARS-CoV-2 infection and we outline hypotheses to explain these findings, including the possible role of cirrhosis-associated immune dysfunction. This finding contrasts with outcome data in pharmacologically immunosuppressed patients after liver transplantation who seem to have comparatively better outcomes from COVID-19 than those with advanced liver disease. Finally, we discuss the approach to SARS-CoV-2 vaccination in patients with cirrhosis and after liver transplantation and predict how changes in social behaviours and clinical care pathways during the pandemic might lead to increased liver disease incidence and severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.